Global Oncology Ablation Market Outlook: 2015-2020 (2nd Edition)

March 2016 | 172 pages | ID: G658BDA8473EN
Meticulous Market Research Pvt. Ltd.

Abstracts

Oncology Ablation is the minimal invasive treatment that is used to destroy or inactive the cancer cells and tumors. The market for oncology ablation is on the rise due to increasing number of cancer diagnosis and high acceptance rate among the cancer community across the world. Over the traditional treatment, oncology ablation has many advantages as it is minimal invasive treatment that makes the recovery easy and quick; also it provides relief to patients Who are reluctant to go for a surgery. Image guided ablation treatments promises the accuracy in destruction of tumor cells without damaging the uninfected cells. The research report titled “Global Oncology Ablation Market Outlook: 2015-2020” provides in-depth analysis of oncology ablation market in four major geographies. The report also emphasizes on the current trends in oncology ablation, market size, market share, recent developments, and forecasts till 2020.

The study offers a comprehensive analysis of oncology ablation market with respect to various technologies and type of cancer. The technologies analyzed in this report are radiofrequency ablation, microwave ablation, cryoablation, ethanol ablation, irreversible electroporesis (IRE), light (laser ablation), and ultrasound ablation; whereas, the cancer types analyzed in the report are lung cancer, liver cancer, breast cancer, kidney cancer, colorectal cancer and prostate cancer. Comprehensive geographical analysis of the oncology ablation is provided by segmenting the global market on the basis of major continents, namely, North America, Europe, Asia Pacific, and RoW (Rest of the World) Which are further analyzed at a country level.

The report offers meticulous analysis of market dynamics, burning issues, and technological landscape of the global oncology ablation market. The report provides the competitive landscape of the major players in this market such as AngioDynamics (U.S.), Covidien (Ireland), Boston Scientific (U.S.), BSD Medical (U.S.), Galil Medical (U.S.), Misonix (U.S), Varian Medical Systems (U.S), Elekta AB (Sweden), Accuray .(U.S), HealthTronics (U.S.), Celon AG (Germany), NeuWave Medical (U.S.), SonaCare Medical (U.S), MedWaves Incorporated (U.S), RF Medical Co. (Korea), STARMed Co. (Korea), and APRO KOREA (Korea) with detailed analysis of their product portfolio, financials, and recent developments.

Key questions answered in the report-

• Which are the high growth market segments in terms of technology and applications?
• What are the market forecasts and estimates from the period 2015-2020?
• What are the major drivers, restrains, threats, and opportunities in the global oncology ablation market?
• What are the burning issues of the global oncology ablation market?
• Who are the major suppliers/players in the global oncology ablation market and What share of the market do they hold?
• What is the competitive landscape and Who are the market leaders by sub-region in the global oncology ablation market?
• What are the recent developments in the global oncology ablation market?
• What are the different strategies adopted by the major players in the global oncology ablation market?
• What are the local emerging players in different regions/ countries and how do they compete with the global players?
• What are the geographical trends and high growth regions?

Contents

1 INTRODUCTION TO GLOBAL ONCOLOGY ABLATION MARKET

1.1 Market Ecosystem
  1.1.1 Technologies
  1.1.2 Cancer Types
1.2 Report Elucidation
1.3 Market Buzz and Foreground
1.4 Research Methodology
  1.4.1 Secondary Research
  1.4.2 Primary Research
  1.4.3 Market Analytics

2 EXECUTIVE SUMMARY

3 MARKET INSIGHTS

3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Impact Analysis
3.6 Market Trends
3.7 Market Share Analysis
3.8 Technology Assessment
3.9 Products Assessment
  3.9.1 Commercialized
  3.9.2 Pipeline
3.10 Major Research Studies in Oncology Ablation

4 GLOBAL ONCOLOGY ABLATION MARKET, BY TECHNOLOGY

4.1 Radiofrequency Ablation
4.2 Microwave Ablation
4.3 Cryoablation
4.4 Ethanol Ablation
4.5 Irreversible Electroporesis (IRE)
4.6 Light (Laser Ablation)
4.7 Ultrasound
4.8 Others

5 GLOBAL ONCOLOGY ABLATION MARKET, BY TYPE OF CANCER

5.1 Liver Cancer
  5.1.1 Primary Liver Cancer
    5.1.1.1 Hepatocellular carcinoma (HCC)
    5.1.1.2 Cholangiocarcinoma/Bile duct cancer
    5.1.1.3 Angiosarcoma
  5.1.2 Metastatic
5.2 Prostate Cancer
  5.2.1 Acinar Adenocarcinoma
  5.2.2 Ductal adenocarcinoma
  5.2.3 Transitional cell (or urothelial) cancer
  5.2.4 Squamous cell cancer
  5.2.5 Carcinoid
  5.2.6 Small cell cancer
  5.2.7 Sarcomas and sarcomatoid cancers
5.3 Breast Cancer
  5.3.1 Ductal carcinoma
  5.3.2 Lobular carcinoma
  5.3.3 Inflammatory
  5.3.4 Triple-negative
  5.3.5 Paget disease of the nipple
  5.3.6 Phyllodes tumor
  5.3.7 Angiosarcoma
5.4 Lung Cancer
  5.4.1 Small cell lung cancer
  5.4.2 Non small cell lung cancer
5.5 Kidney Cancer
5.6 Colorectal Cancer

6 ONCOLOGY ABLATION MARKET, BY GEOGRAPHY

6.1 North America
  6.1.1 U.S.
  6.1.2 Canada
6.2 Europe
  6.2.1 Germany
  6.2.2 France
  6.2.3 U.K.
  6.2.4 Italy
  6.2.5 Spain
  6.2.6 Russia
  6.2.7 Rest of Europe
6.3 Asia-Pacific
  6.3.1 China
  6.3.2 India
  6.3.3 Japan
  6.3.4 Rest of Asia Pacific
6.4 Rest of the World

7 COMPETITIVE LANDSCAPE- GLOBAL ONCOLOGY ABLATION MARKET

7.1 Agreements and Partnerships
7.2 Mergers and Acquisitions
7.3 New Product Launches
7.4 Expansions
7.5 Other Developments

8 COMPANY PROFILES

8.1 Accuray Inc.
  8.1.1 Company Overview
  8.1.2 Financials
  8.1.3 Product Portfolio
  8.1.4 Key Developments
8.2 AngioDynamics
  8.2.1 Company Overview
  8.2.2 Financials
  8.2.3 Product Portfolio
  8.2.4 Key Developments
8.3 APRO KOREA
  8.3.1 Company Overview
  8.3.2 Financials
  8.3.3 Product Portfolio
  8.3.4 Key Developments
8.4 Boston Scientific
  8.4.1 Company Overview
  8.4.2 Financials
  8.4.3 Product Portfolio
  8.4.4 Key Developments
8.5 BSD Medical
  8.5.1 Company Overview
  8.5.2 Financials
  8.5.3 Product Portfolio
  8.5.4 Key Developments
8.6 Celon AG (Olympus)
  8.6.1 Company Overview
  8.6.2 Financials
  8.6.3 Product Portfolio
  8.6.4 Key Developments
8.7 Covidien
  8.7.1 Company Overview
  8.7.2 Financials
  8.7.3 Product Portfolio
  8.7.4 Key Developments
8.8 Elekta AB
  8.8.1 Company Overview
  8.8.2 Financials
  8.8.3 Product Portfolio
  8.8.4 Key Developments
8.9 Galil Medical
  8.9.1 Company Overview
  8.9.2 Financials
  8.9.3 Product Portfolio
  8.9.4 Key Developments
8.10 HealthTronics Inc.
  8.10.1 Company Overview
  8.10.2 Financials
  8.10.3 Product Portfolio
  8.10.4 Key Developments
8.11 MedWaves Incorporated
  8.11.1 Company Overview
  8.11.2 Financials
  8.11.3 Product Portfolio
  8.11.4 Key Developments
8.12 Misonix Inc.
  8.12.1 Company Overview
  8.12.2 Financials
  8.12.3 Product Portfolio
  8.12.4 Key Developments
8.13 NeuWave Medical
  8.13.1 Company Overview
  8.13.2 Financials
  8.13.3 Product Portfolio
  8.13.4 Key Developments
8.14 RF Medical Co. Ltd
  8.14.1 Company Overview
  8.14.2 Financials
  8.14.3 Product Portfolio
  8.14.4 Key Developments
8.15 SonaCare Medical
  8.15.1 Company Overview
  8.15.2 Financials
  8.15.3 Product Portfolio
  8.15.4 Key Developments
8.16 STARMed Co. Ltd
  8.16.1 Company Overview
  8.16.2 Financials
  8.16.3 Product Portfolio
  8.16.4 Key Developments
8.17 Varian Medical Systems
  8.17.1 Company Overview
  8.17.2 Financials
  8.17.3 Product Portfolio
  8.17.4 Key Developments